Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Parkinson's Disease Research, Education and Clinical Center (PADRECC), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.
Neurotherapeutics. 2020 Oct;17(4):1511-1524. doi: 10.1007/s13311-020-00875-w.
Affective disorders (depression and anxiety), psychosis, impulse control disorders, and apathy are common and sometimes disabling psychiatric conditions in Parkinson disease (PD). Psychiatric aspects of PD are associated with numerous adverse outcomes, yet in spite of this and their high frequency, there remains incomplete understanding of epidemiology, presentation, risk factors, neural substrate, and management strategies. Psychiatric features are typically co- or multimorbid, and there is great intra- and interindividual variability in presentation [1]. The neuropathophysiological changes that occur in PD, as well as the association between PD treatment and particular psychiatric disorders, suggest a neurobiological contribution to many psychiatric symptoms. There is evidence that psychiatric disorders in PD are still under-recognized and undertreated, and although psychotropic medication use is common, randomized controlled trials demonstrating efficacy and tolerability are largely lacking. Future research on neuropsychiatric complications in PD should be oriented toward determining modifiable correlates or risk factors, and most importantly, establishing efficacious and well-tolerated treatment strategies.
情感障碍(抑郁和焦虑)、精神病、冲动控制障碍和冷漠是帕金森病(PD)中常见且有时会导致残疾的精神疾病。PD 的精神方面与许多不良后果相关,但尽管如此,且其发病率较高,但对其流行病学、表现、风险因素、神经基础和管理策略仍缺乏全面的了解。精神疾病的特征通常是共病或多病共存,且表现存在很大的个体内和个体间差异[1]。PD 中发生的神经病理生理学变化,以及 PD 治疗与特定精神障碍之间的关联,表明许多精神症状与神经生物学有关。有证据表明,PD 中的精神障碍仍未得到充分认识和治疗,尽管精神药物的使用很常见,但缺乏证明疗效和耐受性的随机对照试验。未来 PD 神经精神并发症的研究应侧重于确定可改变的相关性或风险因素,最重要的是,建立有效且耐受良好的治疗策略。